Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (683) 683
Publication (59) 59
Patent (25) 25
Book Chapter (12) 12
Book / eBook (9) 9
Book Review (4) 4
Web Resource (3) 3
Conference Proceeding (1) 1
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (394) 394
index medicus (330) 330
tuberculosis (272) 272
infectious diseases (207) 207
female (115) 115
microbiology (113) 113
infectious disease (104) 104
male (103) 103
adult (91) 91
medicine, general & internal (85) 85
respiratory system (85) 85
mycobacterium-tuberculosis (82) 82
diagnosis (80) 80
pulmonary tuberculosis (78) 78
antitubercular agents - therapeutic use (76) 76
immunology (69) 69
public health (69) 69
abridged index medicus (67) 67
global health (65) 65
pulmonary/respiratory (65) 65
infections (61) 61
infectious and parasitic diseases (57) 57
drug resistance (55) 55
tuberculosis - prevention & control (55) 55
health aspects (54) 54
middle aged (54) 54
mortality (54) 54
tuberculosis - epidemiology (54) 54
epidemiology (53) 53
infection (48) 48
tuberculosis - diagnosis (48) 48
tuberculosis - drug therapy (47) 47
care and treatment (46) 46
research (46) 46
risk factors (46) 46
mycobacterium tuberculosis (44) 44
hiv (43) 43
internal medicine (41) 41
tuberculosis, multidrug-resistant - drug therapy (40) 40
hospitals (39) 39
medicine (37) 37
adolescent (36) 36
mycobacterium tuberculosis - immunology (36) 36
antitubercular agents (35) 35
human immunodeficiency virus--hiv (35) 35
patients (34) 34
world health organization (34) 34
animals (33) 33
disease (33) 33
medical research (33) 33
mycobacterium tuberculosis - drug effects (33) 33
hiv infections - complications (32) 32
public, environmental & occupational health (32) 32
treatment outcome (32) 32
tuberculosis, pulmonary - diagnosis (32) 32
child (31) 31
prevalence (31) 31
surveillance (31) 31
sensitivity and specificity (30) 30
analysis (29) 29
drug therapy (29) 29
aged (28) 28
children (28) 28
critical care medicine (28) 28
multidrug-resistant tuberculosis (27) 27
tuberculosis - immunology (27) 27
vaccines (27) 27
clinical trials (26) 26
epidemics (26) 26
developing countries (25) 25
human necessities (25) 25
hygiene (25) 25
medical or veterinary science (25) 25
preparations for medical, dental, or toilet purposes (25) 25
prevention (25) 25
research article (25) 25
tuberculosis, multidrug-resistant - epidemiology (25) 25
coronavirus infections - epidemiology (24) 24
medical colleges (24) 24
polymerase chain reaction (24) 24
young adult (24) 24
a300 clinical medicine (23) 23
control (23) 23
disease outbreaks (23) 23
drug resistance in microorganisms (23) 23
incidence (23) 23
tropical medicine (23) 23
tuberculosis, multidrug-resistant - diagnosis (23) 23
zambia (23) 23
antigens (22) 22
biomarkers (22) 22
communicable diseases (22) 22
immune response (22) 22
pneumonia (22) 22
studies (22) 22
africa (21) 21
mycobacterium tuberculosis - isolation & purification (21) 21
saudi-arabia (21) 21
specific therapeutic activity of chemical compounds ormedicinal preparations (21) 21
sub-saharan africa (21) 21
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (724) 724
French (6) 6
Portuguese (6) 6
Finnish (3) 3
German (3) 3
Swedish (3) 3
Norwegian (2) 2
Danish (1) 1
Hungarian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Lifeline: Alimuddin Zumla
by Alimuddin Zumla
The Lancet, ISSN 0140-6736, 06/2003, Volume 361, Issue 9374, p. 2092
  Alimuddin Zumla is Professor of Infectious Diseases and International Health at University College London, London, UK, and Consultant Infectious Diseases... 
Disease | Educators
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections
by Zumla, Alimuddin
Current Opinion in Pulmonary Medicine, ISSN 1070-5287, 05/2013, Volume 19, Issue 3, pp. 189 - 191
SYSTEMATIC ANALYSIS | GLOBAL BURDEN | 21 REGIONS | RESPIRATORY SYSTEM | DISEASE | Respiratory Tract Infections - therapy | Respiratory Tract Infections - diagnosis | Humans | Respiratory Tract Infections - prevention & control | Edited by Alimuddin Zumla | INFECTIOUS DISEASES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Middle East respiratory syndrome
by Zumla, Alimuddin, Prof and Hui, David S, Prof and Perlman, Stanley, Prof
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9997, pp. 995 - 1007
Summary Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus... 
Internal Medicine | DROMEDARY CAMELS | MEDICINE, GENERAL & INTERNAL | NEUTRALIZING ANTIBODIES | IMMUNE-RESPONSES | CLINICAL-ASPECTS | TO-HUMAN TRANSMISSION | MERS-COV | SYNDROME CORONAVIRUS INFECTION | CRITICALLY-ILL PATIENTS | FUNCTIONAL RECEPTOR | SAUDI-ARABIA | Epidemics | Coronavirus Infections - diagnosis | Humans | Middle Aged | Child, Preschool | Infant | Male | Coronavirus Infections - transmission | Middle East | Young Adult | Camelus - virology | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Animals | Coronavirus Infections - epidemiology | Coronavirus Infections - therapy | Adolescent | Aged, 80 and over | Adult | Female | Aged | Child | Saudi Arabia | Acute respiratory distress syndrome | Comorbidity | Mortality | United Kingdom | Respiratory agents | Health aspects | Disease prevention | Viruses | Respiratory diseases | Prevention | Coronavirus | Treatment | Pathogenesis | Clinical | MERS-CoV | MERS | Middle East Respiratory Syndrome | Epidemiology | Public health | Virology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Tuberculosis
by Lawn, Stephen D and Zumla, Alimuddin I
The Lancet, ISSN 0140-6736, 07/2011, Volume 378, Issue 9785, pp. 57 - 72
Tuberculosis results in an estimated 1·7 million deaths each year and the worldwide number of new cases (more than 9 million) is higher than at any other time... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. The return of the white plague
: global poverty and the 'new' tuberculosis
by Gandy, Matthew and Zumla, Alimuddin
2003, ISBN 9781859846698, vi, 330
Medical policy | Tuberculosis | Poverty
Book
Details down arrow
6. Tuberculosis
: a subject collection from Cold Spring Harbor perspectives in medicine
by Zumla, Alimuddin, editor and Rubin, Eric J., editor and Kaufmann, S. H. E. editor. (Stefan H. E.)
2015, ISBN 1621820734, xii, 655
Mycobacterium tuberculosis | Tuberculosis
Book
Details down arrow
7. Full Text Advances in the development of new tuberculosis drugs and treatment regimens
by Zumla, Alimuddin and Nahid, Payam and Cole, Stewart T
Nature Reviews Drug Discovery, ISSN 1474-1776, 05/2013, Volume 12, Issue 5, pp. 388 - 404
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen,... 
IN-VITRO | RESISTANT TUBERCULOSIS | ATP SYNTHASE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | EARLY BACTERICIDAL ACTIVITY | PULMONARY TUBERCULOSIS | BENZOTHIAZINONES | PHARMACOLOGY & PHARMACY | ANTIRETROVIRAL THERAPY | DOSE RIFAMPIN | MOXIFLOXACIN | KILL MYCOBACTERIUM-TUBERCULOSIS | Drug Evaluation, Preclinical - trends | Humans | Drug Discovery - trends | Clinical Trials as Topic | Mycobacterium tuberculosis - drug effects | Anti-Bacterial Agents - therapeutic use | Clinical Trials, Phase III as Topic | Drug Resistance, Multiple, Bacterial | Tuberculosis - drug therapy | Biomarkers | Research Design | Drug Combinations | Antitubercular Agents - therapeutic use | Clinical Trials, Phase II as Topic | Mycobacterium tuberculosis - genetics | Control | Tuberculosis | Demographic aspects | Causes of | Clinical trials | Antitubercular agents | Product development | Forecasts and trends | Research | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
by Caminero, José A, Dr and Sotgiu, Giovanni, PhD and Zumla, Alimuddin, FRCP and Migliori, Giovanni Battista, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Summary Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally thought to have high mortality rates. However, many cases can... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | INVITRO ACTIVITY | TUBERCLE-BACILLI | INFECTIOUS DISEASES | EARLY BACTERICIDAL ACTIVITY | TREATMENT OUTCOMES | CROSS-RESISTANCE | MDR-TB | XDR-TB | CLAVULANIC ACID | RPOB MUTATIONS | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Tuberculosis : a comprehensive clinical reference
by Zumla, Alimuddin I and Schaaf, H. Simon
2009, ISBN 1416039880, xxvi, 1014
This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage... 
Tuberculosis | Treatment | Pathophysiology | Epidemiology
Book
Details down arrow
10. Tropical lung disease
by Sharma, Om P and Zumla, Alimuddin
2002, Clinics in chest medicine, Volume 23, no. 2., xvii, 528
Book
Details down arrow
11. Full Text Tuberculosis
by Zumla, Alimuddin and Raviglione, Mario and Hafner, Richard and Von Reyn, C. Fordham
New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 745 - 755
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Treating drug-resistant tuberculosis
by Zumla, Alimuddin
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 4, pp. 280 - 280
Infectious Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Epidemiology and clinical management of Legionnaires' disease
by Phin, Nick, Prof and Parry-Ford, Frances, MSc and Harrison, Timothy, PhD and Stagg, Helen R, PhD and Zhang, Natalie, MB and Kumar, Kartik, MB and Lortholary, Olivier, Prof and Zumla, Alimuddin, Prof and Abubakar, Ibrahim, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 10, pp. 1011 - 1021
Summary Legionnaires' disease is an important cause of community-acquired and hospital-acquired pneumonia. Although uncommon, Legionnaires' disease continues... 
Infectious Disease | LEGIONELLA-PNEUMOPHILA PNEUMONIA | INFECTIOUS DISEASES | COMMUNITY-ACQUIRED PNEUMONIA | HOSPITALIZED-PATIENTS | RISK-FACTORS | NEW-ZEALAND | PONTIAC FEVER | LONGBEACHAE SEROGROUP 1 | URINARY ANTIGEN | SEQUENCE TYPES | COOLING-TOWERS | Legionnaires' Disease - epidemiology | Global Health | Disease Outbreaks | Legionnaires' Disease - diagnosis | Legionnaires' Disease - transmission | Bacterial Typing Techniques | Humans | Virulence | Legionella pneumophila - classification | Legionella pneumophila - pathogenicity | Legionella pneumophila - isolation & purification | Legionnaires' Disease - therapy | Epidemics | Pneumonia | Hospitals | Bacterial pneumonia | Bacteria | Virulence (Microbiology) | Health aspects | Epidemiology | Public health | Cooling | Mortality | Fountains | Infections | Legionnaires disease | Patients | Resorts & spas | Surveillance | Aerosols | Fatalities
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
by Assiri, Abdullah, MD and Al-Tawfiq, Jaffar A, FACP and Al-Rabeeah, Abdullah A, FRCS and Al-Rabiah, Fahad A, MD and Al-Hajjar, Sami, MD and Al-Barrak, Ali, MD and Flemban, Hesham, MD and Al-Nassir, Wafa N, MD and Balkhy, Hanan H, MD and Al-Hakeem, Rafat F, MD and Makhdoom, Hatem Q, PhD and Zumla, Alimuddin I, Prof and Memish, Ziad A, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 9, pp. 752 - 761
Summary Background Middle East respiratory syndrome (MERS) is a new human disease caused by a novel coronavirus (CoV). Clinical data on MERS-CoV infections are... 
Infectious Disease | CONFIRMATION | INFECTIOUS DISEASES | SARS | FEATURES | Age Factors | Humans | Middle Aged | Cross Infection - mortality | Male | Coronavirus Infections - mortality | Young Adult | Cross Infection - pathology | Coronavirus Infections - epidemiology | Aged, 80 and over | L-Lactate Dehydrogenase - analysis | Adult | Female | Cross Infection - virology | Odds Ratio | Child | Community-Acquired Infections - virology | Saudi Arabia - epidemiology | Fever - pathology | Coronavirus - isolation & purification | Community-Acquired Infections - mortality | Aspartate Aminotransferases - analysis | Diarrhea - virology | Thrombocytopenia - pathology | Community-Acquired Infections - pathology | Adolescent | Aged | Medicine, Experimental | Medical research | Arab countries | Epidemiology | Public health | Hospitals, Military
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
by Zumla, Alimuddin I, Prof and Gillespie, Stephen H, Prof and Hoelscher, Michael, Prof and Philips, Patrick P J, PhD and Cole, Stewart T, Prof and Abubakar, Ibrahim, Prof and McHugh, Timothy D, Prof and Schito, Marco, PhD and Maeurer, Markus, Prof and Nunn, Andrew J, Prof
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 4, pp. 327 - 340
Summary About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | TUBERCLE-BACILLI | INFECTIOUS DISEASES | IN-VITRO | LATENT TUBERCULOSIS | EARLY BACTERICIDAL ACTIVITY | MULTIDRUG-RESISTANT TUBERCULOSIS | PULMONARY TUBERCULOSIS | RANDOMIZED-TRIAL | ANTIRETROVIRAL THERAPY | 2 8-MONTH REGIMENS | Antitubercular Agents - adverse effects | Humans | Tuberculosis, Pulmonary - drug therapy | Clinical Trials as Topic | Drug Discovery | Medication Adherence | Immunotherapy | Biomarkers | Tuberculosis, Pulmonary - therapy | Drug Therapy, Combination | Research Design | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Drugs | Highly active antiretroviral therapy | Antiviral agents | Medical colleges | International cooperation | Antitubercular agents | Drug resistance | Drug approval | Patient compliance | Tuberculosis | Mortality | Clinical trials | Distribution costs | Drug dosages | Developing countries--LDCs | Public health | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights